Corcept Therapeutics CORT

$CORT [Part 2] The 2nd SP drop of 10 pts stems from the suspicion that the company didn't raise its 2026 revenue projection, which stayed as $1.1B to #1.2B - the same as earlier projection. As CORT's management stated durung the ER that the project was raised twice early this year, and the given # was significantly higher than the actual 2025 #. Higher # would have to come from Relacorilant/CS, but it was delayed for a year. Anyway, The $1.1B to $1.2B is significantly higher than $761M for 2025, and is achievable as well as realistic. Better yet, Lifyorli's US sale and its EMA MAA later this month may bring positive surprises to the the final 2026 revenue #. We will see! In short, the SP drops, driven by the dark force from below (DFFB), were not justified. (DFFB: Hedge-fund shorties; MMs; Retail shorties; Hit men hired by the other parties in this category, and Class action vultures.) Folks, we should see SP recovers and surpasses the previous high's soon. GLTA and Cheers!

$CORT The SP dropped twice in the past 15 days, see SP chart below. The 1st drop was after Genmab's Rina-S positive P3 readout, and the 2nd one was after the CORT's Q3/26 ER. It is abundantly clear and widely accepted within the professional societies that Rina-S, a ADC, from Genmab is not a direct competitor to the cortisol modulating Lifyorli. In fact, the adjunct therapy of Lifyorli and Rina-S may further extend the PFS rate for the OC sufferers, although the hypothesis is yet to be clinically tested. The important point is that the approval of Rina-S a year from now may not eat into Lifyorli's markets. (Part 2)

$CORT Corcept (CORT): revenue up 64% to $340.5M, 2026 guidance reiterated Free weekly catalyst newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13 Not investment advice.

$CORT how much is the risk carrying this to FDA decision after last CRL

Dec 17 is the one circled for $CORT relacorilant round two in Cushing syndrome, FDA turned it down last Dec and asked for more data GRACE met its endpoint on blood pressure control, OR 0.17, and the same drug is already approved as Lifyorli in ovarian cancer Q3 beat as well, 1.01 a share vs 0.84 expected, Piper just reiterated overweight at 173 Friday closed 72.77 after a 40% washout month, 39 days out, imo the date does the work here

$CORT Options Flow Leans to Puts: A Smart-Money Check on the Stock. It's down about 10% from a week ago. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=CORT&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=CORT Read the full article for the full details: https://globaltradersacademy.com/articles/corcept-incorporated-cort-options-flow-turns-bearish-a-smart-money-check-on-the?utm_source=stocktwits&utm_medium=social

$CORT Am I the only one thinking this is insanely low?

$CORT expensive stocks